Ascentage Pharma Group International Unsponsored ADR (AAPG) AI Stock Analysis

• Market Cap: $2.59B
• Dividend Yield: N/A
• Average Volume (3M): 8.43K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.59
• Revenue Growth: -56.78%
• EPS Growth: -191.46%
• Country: US
• Employees: 567
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.97
• Shares Outstanding: 93,330,420
• 10 Day Avg. Volume: 7,086
• 30 Day Avg. Volume: 8,425
• PEG Ratio: 1.05
• Price to Book (P/B): 145.04
• Price to Sales (P/S): 39.07
• P/FCF Ratio: -282.48
• Enterprise Value/Market Cap: 1.30
• Enterprise Value/Revenue: 8.63
• Enterprise Value/Gross Profit: 9.50
• Enterprise Value/Ebitda: -3.23
• 1Y Price Target: $48.67
• Price Target Upside: 75.26% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $27.00 ▼(-2.77% Downside)

The score is primarily held back by weak financial quality (ongoing losses, negative cash flow, and high leverage risk) and bearish technical conditions (negative MACD and price below key moving averages). Rapid revenue growth provides some offset, but valuation signals are limited due to negative earnings and no dividend data.

Positive Factors

Rapid revenue growth

Sustained >340% revenue growth year-over-year signals meaningful commercial traction or milestone-driven revenue for a biotech. Over a 2-6 month horizon this improves funding optionality for R&D, validates market demand for assets, and reduces sole reliance on dilutive financing.

FDA IND clearance for APG-3288

IND clearance for a next-gen BTK-targeted degrader represents a structural pipeline expansion into targeted protein degradation. This regulatory milestone enables global clinical development, strengthens proprietary PROTAC platform positioning, and creates durable option value from potential resistant-BTK indications.

Regulatory approval and strong Lisaftoclax data

NMPA approval plus robust Phase II metrics provide an immediate commercial footing in China and clinical validation for the Bcl-2 program. This durable outcome supports revenue diversification, enhances labeling/market access prospects, and underpins strategic partnerships and future global development plans.

Negative Factors

High leverage on balance sheet

Material leverage reduces financial flexibility for a development-stage biotech. Debt servicing and covenant risk can constrain R&D cadence, force unfavorable refinancing in stressed markets, and heighten dilution risk if equity financings are used to shore up solvency over the next several months.

Persistent unprofitability and negative margins

Ongoing negative operating and EBITDA margins indicate the business has not yet converted scientific progress into sustainable profits. Over a 2-6 month horizon this means reliance on external capital continues, limiting self-funding of trials and increasing dependency on partnerships or dilutive financing.

Negative free cash flow and cash conversion challenges

Negative free cash flow and poor cash conversion highlight structural funding needs. Even with reduced negative operating cash flow, persistent cash burn pressures the balance sheet, shortens runway, and makes the company vulnerable to funding cycles, impacting long-term program execution.

Ascentage Pharma Group International Unsponsored ADR Business Overview & Revenue Model

Company Description

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

How the Company Makes Money

Ascentage Pharma generates revenue primarily through the development and commercialization of its pharmaceutical products. The company focuses on advancing its drug candidates through clinical trials and regulatory approval processes, with the potential for revenue from product sales upon successful commercialization. Additionally, Ascentage Pharma may engage in strategic partnerships or collaborations with other pharmaceutical companies, which can provide upfront payments, milestone payments based on development progress, and royalties on future product sales. These partnerships are crucial for funding research and development activities and expanding the company's reach in global markets.

Ascentage Pharma Group International Unsponsored ADR Financial Statement Overview

Summary

Despite strong revenue growth, Ascentage Pharma Group faces significant profitability and cash flow challenges. High debt levels and negative equity ratios indicate financial risk, while persistent negative net income and cash flows highlight the need for strategic improvements.

Income Statement

The company's revenue has seen significant growth from 2023 to 2024, with a revenue increase of over 340%. However, the company remains unprofitable with a negative net profit margin, and the EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges in achieving profitability.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio, indicating significant leverage which could be risky. The equity ratio is low, suggesting a potential vulnerability to financial instability. The Return on Equity is negative, reflecting ongoing losses.

Cash Flow

While there was a reduction in negative operating cash flow in 2024, the company continues to experience negative free cash flow. The operating cash flow to net income ratio is negative, indicating challenges in translating earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	390.60M	980.65M	221.98M	209.71M	27.91M	12.45M
Gross Profit	354.93M	951.57M	191.44M	187.71M	24.58M	10.48M
EBITDA	-1.04B	-237.63M	-743.61M	-786.97M	-798.34M	-652.23M
Net Income	-1.16B	-405.43M	-925.64M	-882.92M	-782.42M	-677.61M
Balance Sheet
Total Assets	3.05B	2.62B	2.50B	2.83B	2.94B	1.73B
Cash, Cash Equivalents and Short-Term Investments	1.66B	1.24B	1.07B	1.48B	1.71B	1.02B
Total Debt	1.72B	1.67B	1.80B	1.79B	1.08B	529.70M
Total Liabilities	2.37B	2.34B	2.43B	2.42B	1.71B	884.42M
Stockholders Equity	666.00M	264.19M	60.42M	408.66M	1.23B	846.62M
Cash Flow
Free Cash Flow	235.27M	-135.65M	-782.92M	-890.88M	-1.04B	-861.43M
Operating Cash Flow	243.03M	-111.36M	-726.08M	-653.91M	-604.68M	-609.96M
Investing Cash Flow	-230.76M	-362.04M	21.92M	-384.61M	-466.52M	-107.37M
Financing Cash Flow	-82.14M	314.77M	368.75M	619.27M	1.78B	1.04B

Ascentage Pharma Group International Unsponsored ADR Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 27.77
• 50DMA: Negative
• 100DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AAPG, the sentiment is Negative. The current price of 27.77 is below the 20-day moving average (MA) of 34.27, below the 50-day MA of 37.24, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -1.44 indicates Positive momentum. The RSI at 34.89 is Neutral, neither overbought nor oversold. The STOCH value of 11.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AAPG.

Ascentage Pharma Group International Unsponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRNX	64 Neutral	$5.67B	-11.98	-44.42%	―	―	-21.96%
PTGX	61 Neutral	$5.02B	128.45	7.80%	―	-35.39%	-72.97%
IMVT	56 Neutral	$5.20B	-9.25	-95.93%	―	―	-27.70%
MLTX	55 Neutral	$1.29B	―	-54.17%	―	―	-157.74%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KYMR	50 Neutral	$5.77B	-20.61	-32.09%	―	-50.05%	-54.47%
AAPG	42 Neutral	$2.59B	-13.80	-161.90%	―	-56.78%	-191.46%

Ascentage Pharma Group International Unsponsored ADR Corporate Events

Ascentage Pharma Wins FDA IND Clearance for BTK Degrader APG-3288 to Enter Global Phase I Trial

On January 6, 2026, Ascentage Pharma Group International announced that the U.S. Food and Drug Administration had granted investigational new drug clearance for APG-3288, a novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader developed using the company’s proprietary PROTAC platform, enabling the launch of a global, multicenter Phase I trial in patients with relapsed or refractory B‑cell and other hematologic malignancies. The move significantly broadens Ascentage’s innovative hematology pipeline and positions the company at the forefront of BTK-targeted protein degradation, as APG-3288 is designed to selectively degrade both wild-type and BTK mutant forms associated with resistance to existing BTK inhibitors, potentially overcoming a key mechanism of treatment failure and creating opportunities for future combination regimens with the company’s own small‑molecule agents, including its commercialized oncology drugs.

The most recent analyst rating on (AAPG) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock, see the AAPG Stock Forecast page.

Ascentage Pharma to Present at J.P. Morgan Healthcare Conference

On December 17, 2025, Ascentage Pharma announced its participation in the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 14, 2026, in San Francisco, CA. The company’s management plans to present their advancements in biopharmaceutical research and commercialization, focusing on innovative treatments for cancer. This presentation highlights strategic opportunities for Ascentage Pharma to bolster its industry positioning, showcase its expanding global trials and partnerships, and engage with key stakeholders and investors in the healthcare sector.

The most recent analyst rating on (AAPG) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock, see the AAPG Stock Forecast page.

Ascentage Pharma Showcases Promising Data for Olverembatinib at ASH 2025

On December 8, 2025, Ascentage Pharma presented updated data on Olverembatinib at the ASH Annual Meeting, showcasing its potential as a second-line treatment for chronic myeloid leukemia in chronic-phase (CML-CP). The data revealed a 76.7% complete cytogenetic response rate in patients who failed second-generation TKI first-line therapy, with responses deepening over time. The study highlighted Olverembatinib’s efficacy and safety, supporting its advancement to earlier treatment lines and broader clinical application. The drug is already approved in China for certain CML indications and is being evaluated in global Phase III studies for various conditions. This development reaffirms Ascentage Pharma’s commitment to addressing unmet medical needs and strengthens its position in the global hematology field.

The most recent analyst rating on (AAPG) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock, see the AAPG Stock Forecast page.

Ascentage Pharma Unveils Promising Lisaftoclax Data at ASH 2025

On December 6 and December 8, 2025, Ascentage Pharma presented significant data at the American Society of Hematology Annual Meeting regarding Lisaftoclax, a Bcl-2 inhibitor. The data from the Phase II study demonstrated Lisaftoclax’s efficacy and safety in treating relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in patients who had failed prior treatments, including Bruton’s tyrosine kinase inhibitors. The study highlighted an objective response rate of 62.5% and a median progression-free survival of 23.89 months, showcasing Lisaftoclax as a promising treatment option for high-risk patients. These findings underscore the drug’s potential impact on Ascentage Pharma’s market positioning and its commitment to addressing unmet clinical needs in hematology.

The most recent analyst rating on (AAPG) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock, see the AAPG Stock Forecast page.

Ascentage Pharma to Highlight Key Data from ASH 2025 in Upcoming Webcast

On December 1, 2025, Ascentage Pharma announced it will host an investor webcast on December 11, 2025, to highlight key data from the 67th American Society of Hematology Annual Meeting. This event will provide updates on the company’s innovative portfolio and pipeline, featuring presentations by the management team. The webcast aims to reinforce Ascentage Pharma’s position in the biopharmaceutical industry by showcasing its ongoing research and development efforts, potentially impacting stakeholders by enhancing the company’s visibility and credibility in the market.

The most recent analyst rating on (AAPG) stock is a Sell with a $33.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock, see the AAPG Stock Forecast page.

Ascentage Pharma Announces New RSU and Share Option Grants

On November 27, 2025, Ascentage Pharma Group International announced the further grant of awards under its 2022 RSU Scheme and the grant of options under the Post IPO Share Option Scheme. This initiative involves the allocation of 1,304,457 RSUs to 146 selected individuals, including key executives and service providers, representing approximately 0.35% of the company’s total issued share capital. The move is part of the company’s strategy to incentivize and retain talent, which is crucial for its long-term growth and competitiveness in the biopharmaceutical industry.

The most recent analyst rating on (AAPG) stock is a Sell with a $33.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock, see the AAPG Stock Forecast page.

Ascentage Pharma’s Olverembatinib Shows Promise in Rare GIST Treatment

On November 24, 2025, Ascentage Pharma announced the publication of promising Phase Ib clinical trial results for olverembatinib in treating succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST), a rare and challenging cancer subtype. The study, published in the prestigious journal Signal Transduction and Targeted Therapy, showed that olverembatinib demonstrated significant efficacy and safety, with a clinical benefit rate of 84.6% and a median progression-free survival of 25.7 months. This advancement highlights a novel mechanism of action involving lipid metabolism modulation, offering a potential new treatment avenue for SDH-deficient GIST, which currently lacks effective therapies.

The most recent analyst rating on (AAPG) stock is a Sell with a $33.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock, see the AAPG Stock Forecast page.

Ascentage Pharma to Engage Investors at December 2025 Conferences

On November 19, 2025, Ascentage Pharma announced its participation in three investor conferences in December 2025, signaling its active engagement with the investment community. This participation could enhance the company’s visibility and investor relations, potentially impacting its market positioning and stakeholder engagement.

The most recent analyst rating on (AAPG) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock, see the AAPG Stock Forecast page.

Ascentage Pharma to Engage Investors at November Conferences

On October 29, 2025, Ascentage Pharma announced its participation in two upcoming investor conferences in November 2025, namely the Goldman Sachs APAC Healthcare Corporate Day and the Stifel 2025 Healthcare Conference. This participation underscores the company’s active engagement with the investment community, potentially enhancing its visibility and investor relations, which could influence its market positioning and stakeholder interests.

The most recent analyst rating on (AAPG) stock is a Sell with a $33.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock, see the AAPG Stock Forecast page.